What Siligaz Treats: Main Uses and Benefits

Siligaz is applied across domains where additional symptomatic support is needed to address discomfort and functional strain related to upper gastrointestinal issues.

This medication may assist with managing symptoms of nausea and is commonly used to help manage the disruptive manifestation of vomiting. It is relevant for easing conditions characterized by periods of heightened symptoms linked to upper gastrointestinal motility disorders—such as diabetic or idiopathic gastroparesis—and is also applied when gastrointestinal side effects arise from certain concurrent medications.

The medication is used in situations involving certain distressing symptoms:

“The medication is often used when groups of symptoms appear suddenly or fluctuate, providing support that helps ease the overall symptom burden.”

It helps address symptom clusters that may interfere with daily comfort, including feelings of persistent epigastric fullness, bloating, and early satiety, and supports the patient during difficult episodes by easing distress. Furthermore, it is applied in scenarios requiring supportive symptom management, such as in palliative care settings.

---

Summary: Support for Symptom Management

Domain	Key Symptoms Managed	Patient Benefit
Antiemetic	Nausea, Vomiting	Supports patients during episodes of heightened discomfort
Gastroprokinetic	Fullness, Bloating, Early Satiety	Contributes to easing the overall symptom load and helps improve day-to-day comfort

Regulatory References

1. Health Canada Product Monograph

Eligibility and Contraindications for Siligaz (Domperidone)

Official regulatory information strictly defines the populations eligible to use Siligaz and identifies groups who must not use the medicine. Eligibility criteria may vary by region; the following rules are based on global regulatory standards.

Approved Populations: Adults and adolescents 12 years of age or older who weigh at least 35 kg are generally eligible for use. Patients with mild hepatic impairment do not require dose modification.

Absolute Contraindications (Must Not Use):

• Patients with moderate or severe hepatic impairment (liver failure).
• Individuals with known existing prolongation of cardiac conduction intervals (QTc), congestive heart failure, or significant electrolyte disturbances (e.g., hypokalemia).
• Patients with a prolactin-releasing pituitary tumour (prolactinoma).
• Conditions where stimulating gastrointestinal movement is harmful, such as gastrointestinal haemorrhage, mechanical obstruction, or perforation.
• Concomitant use with specific QT-prolonging medicines or potent CYP3A4 inhibitors.

Restricted and Age-Related Use:

• Use in children less than 12 years of age or adolescents under 35 kg is not established and generally not recommended by regulators.
• Older adults (over 60 years) have an observed higher risk of serious cardiac events, requiring caution.
• For severe renal impairment, the patient population is restricted to a reduced dosing frequency.
• Use during pregnancy is only permitted when justified by the anticipated therapeutic benefit; the drug is not recommended while breastfeeding due to excretion in human milk.

Interactions with other medicines and products

Siligaz is formally contraindicated with two main classes of substances. Co-administration with potent CYP3A4 inhibitors (e.g., Ketoconazole, Clarithromycin) is prohibited because these agents significantly reduce the clearance of Siligaz, leading to increased plasma exposure. This increased exposure heightens the risk of cardiotoxicity.

The second prohibition applies to all medicinal products known to prolong the QTc interval (e.g., Amiodarone, Pimozide), due to an officially documented additive pharmacodynamic risk to cardiac function. Grapefruit juice is also formally contraindicated for the same metabolic reason.

---

Administration Timing and Other Interactions

Category	Regulatory Statement
Timing-Separation Rule	Antacids and antisecretory agents must not be taken simultaneously with oral Siligaz to avoid reduced bioavailability.
Pharmacodynamic Antagonism	Anticholinergic drugs may compromise the prokinetic effect of Siligaz.
Co-administered Drug Exposure	Co-administration with Levodopa is documented to increase its plasma concentration.
Population Constraint	The risk of serious cardiovascular events is officially heightened in elderly patients (>60 years) when combined with contraindicated substances.

---

The interaction profile includes the constraint that Siligaz is strictly contraindicated in patients with moderate or severe hepatic impairment due to the resulting risk of increased systemic exposure.

How Siligaz Works: Pharmacodynamic Mechanism

The action of Siligaz derives from two distinct mechanistic domains. The Simethicone component operates through a physical, non-systemic surfactant mechanism entirely within the gastrointestinal (GI) lumen. It specifically reduces the surface tension of the liquid films stabilizing small gas bubbles, causing them to coalesce into larger gas masses. The resulting physiological effect is a reduction in localized physical distension on the intestinal walls, facilitating gas mobility.

Simultaneously, the Alverine Citrate component exerts a pharmacological effect on GI smooth muscle and sensory nerves. It acts as a calcium channel modulator, inhibiting the necessary Ca^2+ influx into smooth muscle cells required for contraction. This mechanism promotes the inhibition of excessive spasm and supports the regulation of muscle tone. Additionally, Alverine functions as an antagonist at 5 -HT1 A receptors on visceral sensory nerve endings, which dampens the afferent transmission of sensory signals. This action results in a decrease in the sensitivity of gut nerve endings, modifying the perception of visceral signals.

How to Use Siligaz: Official Administration Guidelines

Siligaz (Domperidone) is used at the lowest effective dose for the shortest duration necessary to manage symptoms. Treatment duration for acute symptoms should generally not exceed one week (seven days).

---

Official Dosing and Frequency

Population (Age/Weight)	Route/Form	Single Dose	Maximum Daily Dose	Frequency
Adults & Adolescents (≥ 12 years and ≥ 35 kg)	Oral (Tablets/Suspension)	10 mg	30 mg	Up to three times per day
Adults	Rectal (Suppositories)	30 mg	60 mg	Up to two times per day
Pediatric (< 35 kg)	Oral Suspension only	0.25 mg/kg bodyweight	0.75 mg/kg bodyweight	Up to three times per day

---

Administration Requirements

Timing and Intake: Oral Siligaz should be taken before meals—ideally 15 to 30 minutes prior—as consuming it after food is documented to delay drug absorption.

Dosing Interval: A minimum interval of 8 hours must be observed between subsequent doses.

Missed Dose Instructions: If a dose is missed, it should be omitted, and the usual dosing schedule resumed with the next planned dose. Do not take a double dose to compensate for the missed one.

Population Adjustments: For patients with severe renal impairment, the dosing frequency is reduced to once or twice daily, depending on the degree of impairment, and the dose may require reduction. Due to the need for accurate dosing, tablets and suppositories are considered unsuitable for children and adolescents weighing less than 35 kg.

Research Evidence / Overview of Studies for Siligaz

Evidence for Use in Acute Nausea and Vomiting

Research exploring Siligaz was evaluated using short-term Randomized Controlled Trials (RCTs) and systematic reviews of these trials. This study structure was used in research exploring short-term symptom changes related to acute conditions.

The studies monitored outcomes related to episodic or acute changes in patient-reported symptoms. Researchers examined how often people experienced vomiting and used scales to measure the intensity of nausea. Findings describe patterns observed in the studies over short follow-up durations, typically less than one week. The short follow-up periods mean that conclusions regarding long-term maintenance are limited.

Evidence for Gastroprokinetic Uses (e.g., Gastroparesis)

For chronic, underlying digestive issues like gastroparesis, studies exploring Siligaz have employed different methodologies, which is common given the long-term nature of these diseases. Siligaz was evaluated in patients facing symptoms like epigastric fullness, bloating, and early satiety, all conditions marked by functional limitations related to slow stomach movement.

The evidence for this application is often derived from long-term open-label studies and data collected from specialized Observational Registries. Studies monitored outcomes related to patient-reported outcomes describing perceived discomfort. A key limitation is the lack of large, long-term, placebo-controlled trials for chronic conditions, which means certainty remains low regarding long-term outcomes.

Research in Specific Populations and Age Groups

Research has explored the use of Siligaz across various age groups. The research was conducted in adults with comorbidities like diabetes, but data for other specific populations remain insufficient.

Siligaz was evaluated in adolescents and some children, but regulators have noted that data for certain groups remain insufficient. Consequently, subgroup findings are uncertain in specific pediatric cohorts, and studies exploring age-related differences in response are still required to strengthen the evidence base.

Key Studies & References

1. Health Canada Product Monograph for Domperidone (Used to confirm approved indications and specific populations)

Common questions about Siligaz (FAQ)

Q: Why is Siligaz not suitable for children under 35 kg?

Regulatory authorities have removed the approved use of Siligaz for children under 12 years of age or those weighing less than 35 kg. This restriction was applied because studies did not show a significant difference in how effective the medicine was compared to placebo for relieving symptoms of nausea and vomiting in this specific patient group.

---

Q: Does Siligaz help with symptoms of gastroparesis?

Official information indicates that Siligaz is authorized as a gastroprokinetic agent, meaning it helps to influence movement in the stomach and digestive tract. Its authorized purpose is to alleviate symptoms associated with slow stomach movement, which includes uncomfortable feelings such as epigastric fullness, bloating, and early satiety.

---

Q: How long does it take for Siligaz to start working?

Official product information indicates that the effects of an oral dose may be observed within 30 to 60 minutes after administration. The drug’s absorption may be affected by the timing of intake relative to meals, which is why specific administration guidelines are provided in the 'How to Use' section.

---

Q: What information is available about taking too much Siligaz (overdose)?

Immediate medical attention is necessary if an overdose is suspected. Taking too much Siligaz has been documented to potentially lead to symptoms such as feeling sleepy or disoriented. More serious symptoms noted in regulatory documents include uncontrolled or unusual movements, particularly involving the eyes or tongue, and possible changes in heart rhythm.

---

Q: What is the proper way to dispose of unused Siligaz?

To comply with safety and environmental regulations, official guidance specifies that Siligaz should not be thrown away in household trash or poured down a sink or toilet. Proper disposal typically involves utilizing a medicine take-back program or asking a pharmacist for specific instructions.

The storage and disposal of Siligaz (Domperidone) must strictly follow the conditions detailed in official regulatory documentation to ensure product stability and safety.

Storage Conditions

Item	Requirement
Temperature	Store at room temperature, typically 15 C to 30 C (59 F to 86 F), or not exceeding 30 C.
Protection	Must be protected from light and moisture and kept away from excessive heat.
Handling	Keep from freezing; specific forms must not refrigerate [Drugs.com]. Must be stored in a closed container.
Child Safety	Must be kept out of the sight and reach of children [Health Canada Product Monograph].

Disposal Requirements

Official disposal instructions prohibit discarding the medicine via wastewater or household trash. Patients are directed to ask a pharmacist how to throw away medicines no longer needed or utilize an official pharmacy take-back program.